摘要
目的:研究趋化因子受体CXCR1在乳腺癌组织中的表达特征,并探讨新辅助化疗前后其表达变化与化疗疗效的关系。方法:选取20例正常乳腺组织,20例乳腺纤维腺瘤,104例乳腺癌标本,免疫组化染色后统计每例标本CXCR1的阳性表达积分,分析不同乳腺疾病CXCR1的表达差异。统计新辅助化疗前后乳腺癌标本CXCR1的阳性表达积分的变化,分析其与化疗病理反应的关系。结果:CXCR1在正常乳腺组织、乳腺纤维腺瘤中低表达,在乳腺癌组织上高表达;其表达与患者的年龄、原发肿瘤的大小无关(P>0.05),与病理分期、癌细胞的分化程度、淋巴结转移个数、激素受体状态及Her2表达情况相关,P<0.05,有统计学意义。新辅助化疗后,癌组织中CXCR1的表达下降,下降幅度越大,其化疗疗效越好。结论:CXCR1的检测对于乳腺疾病的良恶性判断有指导意义,可辅助判断乳腺癌的恶性程度、侵袭性以及预后,CXCR1表达的下降与化疗疗效相关,抑制其表达可能可以提高化疗疗效。
Objective： To investigate the expression of chemokine receptor CXCR1 in the tissues of breast cancer, before and after neo-adjuvant chemotherapy, and to analyze the relationship between the expression and the efficacy of neo-adjuvant chemotherapy.Methods： One hundred and four female cases with breast carcinoma, twenty cases with normal breast tissues, and twenty cases with breast fibroadenoma were collected. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues, and find its expression characteristics. The expression of CXCR1 in breast cancer biopsies and surgical specimens and the relationship between the expression and the efficacy of neo-adjuvant chemotherapy was analyzed. Results： The chemokine receptor CXCR1 was lowly expressed in normal breast tissue and breast fibrodenoma, but highly expressed in breast cancer. It had no significant correlation with patient’s age, primary tumor size（P〉0.05）, but was significantly correlated with pathological stage, tumor cell differentiation, as well as the presence of lymph node metastasis（P〈0.05）. The expression of CXCR1 in breast cancer declined after neo-adjuvant chemotherapy.While the expression declined more significantly, the patient had the better efficacy. Conclusion： Chemokine receptor CXCR1 could be used as an indicator to predict breast disease benign or malignant, auxiliarily to predict the degree of malignancy of breast cancer, its invasive ability and prognosis. It could be also a good indicator to detect the effect of neo-adjuvant chemotherapy and an effective target for anti-cancer therapy.
出处
《现代生物医学进展》
CAS
2015年第24期4659-4663,共5页
Progress in Modern Biomedicine
基金
南京市医学科技发展项目(YKK10080)
关键词
乳腺癌
趋化因子受体
新辅助化疗
靶向治疗
Breast cancer
Chemokine receptor
Neo-adjuvant chemotherapy
Targeted therapy
